

U.S. Securities and Exchange Commission  
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 5, 2006

ORTHODONTIX, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida (State or other jurisdiction of incorporation)	000-27836 Commission File Number	65-0643773 (IRS Employer Identification No.)
--	--	--

1428 Brickell Avenue, Suite 105  
Miami, Florida 33131  
(Address of principal executive offices)

(305) 371-4112  
(Registrant's Telephone Number)

Not Applicable  
(Former name, former address and former fiscal year,  
if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02(d) APPOINTMENT OF NEW DIRECTOR

On July 5, 2006, the directors of Orthodontix, Inc. (the "Company") appointed Dr. Curtis Lockshin to fill one of the vacancies on its Board of Directors. This appointment brings the number of directors on the Orthodontix board to four.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 99.1 Press Release dated July 6, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ORTHODONTIX, INC.  
(Registrant)

Dated: July 5, 2005

By: /s/ Glenn L. Halpryn

-----  
Glenn L. Halpryn  
Chief Executive Officer

Dr. Curtis Lockshin joins Orthodontix, Inc. 's Board of Directors

Miami, Florida July 6, 2006 / OTIX (OTC:BB) Orthodontix announced today that it has appointed Dr. Curtis Lockshin to fill one of the vacancies on its Board of Directors.

"Curt Lockshin brings over 12 years of pharmaceutical experience and leadership skills to this role", said Glenn Halpryn, Chairman and Director of Orthodontix Inc. "We are delighted to welcome Dr. Lockshin to Orthodontix's Board of Directors, and we look forward to benefiting from his substantial experience."

Dr. Lockshin is a consultant with expertise across all areas of drug discovery and development; his consulting activity is presently focused on small companies that seek to leverage their technology assets inside healthcare, biotechnology, and security sectors. While at Sepracor Inc., Dr. Lockshin was instrumental in establishing the company's New Leads program, which delivered novel chemical entities into the preclinical pipeline. At Beyond Genomics, Inc., he co-developed strategies for utilizing the company's technology platforms in clinical trial optimization and prediction of off-target drug activities. Dr. Lockshin is a co-inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. He holds a Bachelor's degree in Life Sciences and a PhD in Biological Chemistry, both from MIT.

This appointment brings the number of directors on the Orthodontix Board to four.

CONTACT: Orthodontix, Inc., Miami  
Glenn L. Halpryn, 305-371-4112